Skip to main content
. Author manuscript; available in PMC: 2020 Jun 25.
Published in final edited form as: Int J Oncol. 2011 Mar 9;38(5):1445–1452. doi: 10.3892/ijo.2011.966

Figure 2.

Figure 2.

Overall survival (OS) in patients treated with bevacizumab plus chemotherapy according to HER2 and p53 status. OS comparing patients with p53-negative tumors to those with p53-positive tumors in HER2-negative group (A) and HER2-positive group (B).